Home > Press Releases

Press Releases (Page 3)

SeaSpine Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Including Record Fourth Quarter 2021 Revenue

CARLSBAD, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today preliminary financial results for the fourth quarter and full year 2021. Fourth Quarter and Full Year 2021 Financial Results (all revenue amounts are preliminary and unaudited) Fourth quarter 2021 global revenue is... ❯❯❯

Surgery Partners Reaffirms 2021 and 2022 Full Year Guidance; David T. Doherty to Assume Role of Chief Financial Officer on February 1, 2022

BRENTWOOD, Tenn., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Members of management of Surgery Partners, Inc. (NASDAQ: SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, will be meeting with investors today, January 10, 2022, as part of the 40th Annual J.P. Morgan Healthcare Conference, including a virtual presentation at 5:15 p.m. ET. Based on results through November 2021, the Company is... ❯❯❯

Press release Biocartis Group NV: BIOCARTIS MEETS 2021 KEY OBJECTIVES

PRESS RELEASE:  REGULATED INFORMATION10 January 2022, 07:00 CET BIOCARTIS MEETS 2021 KEY OBJECTIVES Mechelen, Belgium, 10 January 2022 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announced the Company has achieved its 2021 key business objectives which were focused on three performance indicators: expanded installed base of its rapid and... ❯❯❯

Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection

SAN DIEGO, Jan. 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a research collaboration and exclusive license agreement. The collaboration will focus on development and optimization of patent-pending precision medicine approaches, based on RNA expression signatures, to personalize therapeutic agent... ❯❯❯

Core One Labs Now Also Working to Biosynthesize DMT and Receives License

VANCOUVER, British Columbia, Jan. 08, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that it has progressed its work on biosynthesizing N,N-Dimethyltryptamine (“DMT”) and has been approved by Health Canada to add N,N-Dimethyltryptamine (“DMT”) to the schedule of approved controlled substances under the existing... ❯❯❯

Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference

NORCROSS, Ga., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022. Mr. Joel Lewis, President and Chief Executive Officer, and Dr. Pol F. Boudes, Chief Medical Officer, will be presenting on behalf of the... ❯❯❯

Core One Labs Applauds Health Canada’s Amendments to Special Access Program, Allowing Physicians to Request Patient Access to Psychedelic Treatments

VANCOUVER, British Columbia, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) applauds Health Canada for its recent amendment to the Special Access Programme (SAP), which will now allow physicians to request patient access to psychedelic treatments, including psilocybin-assisted therapy. The amendments under the SAP came into effect as... ❯❯❯

Treatment to Expand Global Library of Medicine with Dermatologic Diseases

VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Treatment.com International Inc. (“Treatment” or the “Company”) (CSE: TRUE), (OTC: TREIF), a healthcare AI technology company, has entered into a research project agreement with the University of Minnesota to add more than 220 dermatologic diseases to their proprietary, responsive AI engine known as the Global Library of Medicine (GLM). The addition of these... ❯❯❯

Surgery Partners, Inc. to Present at Upcoming Investor Conference

BRENTWOOD, Tenn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced that Wayne S. DeVeydt, Executive Chairman of the Board, Eric Evans, Chief Executive Officer and Tom Cowhey, Chief Financial Officer will meet with investors at the J.P. Morgan Virtual Healthcare Conference, including a presentation on... ❯❯❯

Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib

Press release        Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers, utilizing Allarity’s DRP® companion diagnostics Allarity has submitted a new drug application (NDA) for the U.S. approval of dovitinib in renal cell carcinoma (RCC) together with the Dovitinib-DRP® companion diagnostic Cambridge, MA U.S.A. (January 3, 2022) — Allarity Therapeutics,... ❯❯❯